Introduction
The incidence of fungal infection has escalated significantly and is expected to continue to increase for the foreseeable future because of the increase in the number of people whose immune system is compromised by AIDS, ageing, organ transplantation, or cancer therapy. [1] [2] [3] The antifungal drugs for the treatment of fungal infections are limited and their application has become an increasing medical problem. Most of the current antifungal drugs, such as miconazole, simply reduce the growth of fungi. Amphotericin B, on the other hand, is a potent fungicidal agent, but its acute or chronic toxicities 4 limit its clinical use. Reports of in situ or in bloodstream antifungal resistance are also becoming more common. 5 Thus, there is an urgent need to develop novel broad-spectrum antifungal agents with little or no toxicity. 6 Cationic antimicrobial peptides (CAMPs) have emerged as a promising new class of antibiotics. 7 However, there are some limitations of using CAMPs as therapeutic agents. These include sensitivity to high ionic strength, and susceptibility to proteolysis. Despite these shortcomings, several antimicrobial peptides with therapeutic potential have been developed. 8 Their application, due to their unique properties, has been, until recently, limited to a topical use. This may no longer necessarily be the case, since recent findings demonstrated that synthetic antimicrobial peptides can be designed to exert activities in complex biomatrices, including blood and blood fractions. 9 Also, it is important to keep in mind that the in vivo environment is rich in potentially synergic compounds.
Histatins and mucins are two families of human salivary proteins that are important components of the innate host defence system. Ourselves and others have previously reported that histatins possess a significant in vitro antimicrobial activity, especially against fungi such as Candida, Cryptococcus neoformans and Aspergillus fumigatus. [10] [11] [12] [13] [14] [15] The low molecular weight salivary mucin, MUC7, in its full-length form (357 amino acid residues) protects the oral cavity from microbial infections through more general protective mechanisms rather than the direct killing of microorganisms. However, recently, we have discovered that peptides derived from its N-terminal region have a significant and a broad-spectrum in vitro fungicidal and bactericidal activity. [16] [17] [18] These properties, along with their low toxicity for human cells, 19,20 make these peptides promising candidates for the treatment of fungal infection as supplements to conventional antimycotics.
The best antimicrobial treatment may involve drug combination therapy, using two or more drugs each of which has a separate mode of action and each of which results in a distinct mechanism of resistance. Antimicrobial agents in combination can, in certain cases, exhibit improved efficacy, reduce the development of resistant strains and side effects of some currently used antibiotics. 21 Achievement of synergy is one of the major theoretical justifications for combination therapy. Some in vitro studies show that antimicrobial peptides enhance the activity of antibiotics against bacteria 22 28 However, to date, there has been no report on antifungal activity using combinations of salivary CAMPs. We have previously determined that MUC7 20-mer (amino acids 32-51 of the parent MUC7) is a potent agent against a broad range of microorganisms including fungi that are resistant to conventional antifungal drugs, and that it appears to work by a mechanism distinct from that of Hsn5. 18 Further, we have shown that MUC7 12-mer, a 12-amino acid C-terminal fragment of MUC7 20-mer (amino acids 40-51 of MUC7) not only retained but exceeded the antifungal activity of the 20-mer. 29 Its activity is also comparable to that of other CAMPs. 14, 30, 31 Rothstein et al. reported that Hsn5 12-mer (P113), a 12 amino acid fragment of Hsn5, retains anticandidal activity comparable to that of the parent compound. 14 Based on the results of the above studies, we selected the MUC7 12-mer and Hsn5 12-mer for this study where we aimed to examine the antifungal effect of combination of these two peptides, and of MUC7 12-mer with amphotericin B or miconazole against Candida albicans and C. neoformans.
Materials and methods

Peptides and antimycotics
Hsn5 12-mer (AKRHHGYKRKFH, amino acids 4-15 of the parent Hsn5) and MUC7 12-mer (RKSYKCLHKRCR, amino acids 40-51 of the parent MUC7) were custom-synthesized by Bio-Synthesis (Lewisville, TX, USA). HPLC and mass spectrometry assays were carried out to analyse the purity of the peptides. The purity (80%) was taken into consideration in preparation of the stock solution of each peptide for antifungal assays. The peptides were dissolved in sterile double-distilled water at 1 mg/mL; aliquots were freeze-dried and stored at -20°C. For each experiment, the freeze-dried peptides were re-dissolved at 1 mg/mL in sterile double-distilled water. Amphotericin B (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in dimethyl sulphoxide (DMSO) at 1 mg/mL. Miconazole (Sigma Chemical Co., St Louis, MO, USA) was dissolved in sterile double-distilled water at 0.1 mg/mL. For each experiment, cells were cultured freshly from frozen stock on Sabouraud Dextrose Agar (SDA, Difco) for 24 h at 37°C, except for S. cerevisiae S288C, which was grown for 96 h at 30°C. To prepare fungal cell suspension (blastoconidia) for antifungal activity assays, one colony was picked from the plate and resuspended in LYM medium, and the concentration was adjusted to 1 × 10 5 cells/mL.
Antifungal susceptibility test
MICs of MUC7 12-mer and other reference antifungal agents were determined by the broth microdilution method modified by Rothstein et al. 14 Briefly, two-fold serial dilutions of each peptide or antimycotics were prepared with modified RPMI 1640 medium (LYM broth), 14 Each well of the microtitre plate was inoculated with fungal cell suspension to a final concentration of 1 × 10 4 cells per mL and the plates were incubated at 37°C for 24-48 h. Afterwards, the absorbance was measured at 620 nm using a microplate reader (Model 3550, Bio-Rad, Japan) to assess the cell growth. The MIC endpoint was the lowest concentration of antifungal agent that completely inhibited growth or that produced at least 90% reduction in turbidity when compared with that of the drug-free control. The MIC value of two independent experiments was usually the same for a particular isolate; if not, a third test was required and the value from the majority of tests was reported. The minimal fungicidal concentration (MFC) was determined by the method used by Hong et al. 25 Briefly, an aliquot (100 µL) of cell suspension was taken from two wells above the MIC, centrifuged and washed three times with fresh LYM broth. Then each cell suspension was plated on SDA plate, and the fungal cells were enumerated after incubation at 37°C for 48 h. The MFC was defined as the lowest concentration of the peptide in which no growth occurred.
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Chequerboard antifungal assay
In one dimension of a 96-well microtitre plate, two-fold serial dilutions of amphotericin B, or miconazole, or Hsn5 12-mer in LYM were prepared in a volume of 100 µL per well, giving final concentrations from 3.13 to 0.03 mg/L, 10 to 0.16 mg/L, or 12.5 to 0.1 mg/L, respectively. In the second dimension, a two-fold dilution series of MUC7 12-mer in the same broth was added in a volume of 100 µL per well, giving a final concentration of MUC7 12-mer from 12.5 to 0.1 mg/L. Each well of the microtitre plate was inoculated with fungal cell suspension [C. albicans (DIS) or C. neoformans (CN2)], to a final concentration of 1 × 10 4 cells per mL, and the plates were incubated at 37°C for 24-48 h. Afterwards, the absorbance was measured at 620 nm using a microplate reader. The lowest drug concentration that inhibited the growth of the fungal cells was used to determine the fractional inhibitory concentration (FIC), defined as the ratio of the MIC of a drug used in combination to the MIC of the drug tested lone. The FIC index (FICI, the sum of the FICs) was calculated for the most equally effective concentration of drugs. 32 According to the new policy of this journal, fractional inhibitory concentration index (FICI) values ≤0.5 are considered to indicate synergy; 0.5-4.0, no interaction; and >4, antagonism. 33 Each experiment was carried out in duplicate.
Blastoconidia killing assay
Killing assays were carried out essentially as described previously. 18 In brief, 20 µL of two-fold serial dilutions of peptides (50-1.56 µM in LYM) were incubated in duplicate with an equal volume (20 µL) of a C. albicans (DIS) or C. neoformans (CN2) suspension (1 × 10 5 cells/mL) in LYM medium. After incubation at 37°C for 1.5 h, the reactions were diluted 20-fold with 10 mM sodium phosphate buffer, pH 7.4, and aliquots (50 µL, or ∼120 cells) of each sample were plated on SDA. The plates were incubated at 37°C for 1 or 2 days aerobically. The number of colony-forming units (cfu) was counted. Percentage of killing was calculated as: [1 -(amount of viable cells in the test group/amount of viable cells in the control group)] × 100%.
Killing activity in combination was carried out by exposure of the yeast cells to varying concentrations of MUC7 12-mer in LYM and a fixed concentration of the other agent. The concentrations of MUC7 12-mer used were based on ED 50 and ED 90 values of the peptide; they were 6.26, 12.5 and 25 µM for C. albicans, and 0.78, 1.56 and 3.13 µM for C. neoformans. Fixed concentrations of Hsn5 12-mer, amphotericin B or miconazole were: 7.5, 7.5 or 15 µM for C. albicans, and 0.78, 7.5 and 7.5 µM for C. neoformans, respectively. Untreated cells were used as control. Percentage of killing was calculated by the equation given above.
Time-kill curves were determined by incubation of C. albicans (DIS) or C. neoformans (CN2) (20 µL of 1×10 5 cells/mL in LYM) with equal volumes of the peptides (in LYM) at three concentrations (10, 20 or 30 µM). At different time points (0, 5, 15, 30, 45 and 90 min), samples were diluted 20-fold with 10 mM sodium phosphate buffer, pH 7.4, and cell viability was determined by plating on SDA.
Haemolytic assay
Human erythrocytes from healthy individuals were collected in vacuum tubes containing heparin (final concentration 20.4 U/mL) as anticoagulant. The erythrocytes were harvested by centrifugation for 10 min at 2000 rpm at 20°C, and washed three times in PBS (10 mM sodium phosphate, pH 7.4, in 150 mM NaCl). To the pellet, PBS was added to yield a 10% (v/v) erythrocytes/PBS suspension. The 10% suspension was diluted 1:10 either in PBS or isotonic glucose phosphate buffer (IGP, 1 mM potassium phosphate buffer, pH 7.0, supplemented with 287 mM glucose as an osmoprotectant), 19 or LYM supplemented with 287 mM glucose as an osmoprotectant (LYMG). From each suspension, 100 µL was added in duplicate to 100 µL of a two-fold dilution series of peptide in the same buffer in a 96-well V-bottomed microtitre plate (Dynatech Laboratories, Inc, Alexandria, VA, USA). Total haemolysis was achieved with 1% Triton X-100. The plates were incubated for 1 h at 37°C and then centrifuged for 10 min at 2000 r.p.m. at 20°C. From the supernatant fluid, 150 µL was transferred to a flat-bottomed low affinity microtitre plate (Corning, New York, USA), and the absorbance was measured at 450 nm using a microplate reader (Model 3550, Bio-Rad, Japan). The percentage of haemolysis was calculated by: [(A 450 of the peptide-treated sample -A 450 of buffer-treated sample)/(A 450 of Triton X-100-treated sample -A 450 of buffer-treated sample)] × 100%.
Statistical analysis
Each value was determined from at least two independent experiments carried out in duplicate. Statistical significance was evaluated by analysis of variance (ANOVA) followed by Tukey test. A P value of less than 0.05 was considered to be significant. Molar concentrations of peptides resulting in killing 50% or 90% of control cells (ED 50 or ED 90 ) and corresponding 95% confidence limits were determined by PROBIT regression procedure in SPSS (SPSS software package 6.1.2 for Macintosh).
Results
Fungal growth inhibitory activities of MUC7 12-mer and other compounds determined by broth microdilution assays
Many antimicrobial peptides are sensitive to high ionic strength and thus their antimicrobial activity is usually determined by killing assays in low ionic strength buffers rather than by broth dilution assay commonly used for conventional antimicrobials. 8, 14 In order to measure the activity of Hsn5 and Hsn5-derived peptides in terms of MIC, Rothstein et al. 14 developed a modified broth dilution susceptibility test. This broth, designated LYM, is a modified RPMI 1640 medium, which excludes excess of divalent cations and monovalent salt and includes a chelating agent and trace elements. In this study, we used this low ionic strength LYM medium for all susceptibility tests, including the killing assays, to determine the antifungal activity of MUC7 12-mer.
The in vitro susceptibilities of the fungal strains to MUC7 12-mer, Hsn5 12-mer, amphotericin B and miconazole are shown in Table 1 . The data are presented as MIC and MFC of the peptide or drug concentrations required to inhibit (MIC) or kill 90% or greater (MFC) of the fungal strain tested. MUC7 12-mer and Hsn5 12-mer were active against the majority of selected stains, with MIC and MFC values ranging from 3.13 to 6.25 mg/L, with the exception of C. glabrata ATCC 90030. In comparison, the MIC and MFC values for amphotericin B, and miconazole ranged from 0.78 to 6.25 mg/L. Interestingly, for C. krusei and C. neoformans 2406, the MICs and MFCs of the two peptides were 2-5-fold lower than those of amphotericin B. In addition, MFCs of MUC7 12-mer and Hsn5 12-mer for C. albicans ATCC 96112 were two-and four-fold lower, respectively, than those of miconazole.
Growth inhibitory activities of MUC7 12-mer and Hsn5 12-mer using killing assay
Because MUC7 12-mer showed antifungal activity in LYM medium using broth microdilution assay, next we determined how MUC7 12-mer (and Hsn5 12-mer) fungicidal activities in LYM media compared to those in phosphate buffer. 
Time killing assays
Time-kill experiments, carried out with three different concentrations of peptides (10, 20 and 30 µM), indicated differences in killing rate between Hsn5 12-mer and MUC7 12-mer, as well as between C. albicans and C. neoformans (Figure 1) . At a concentration of 30 µM, 90 min of incubation with Hsn5 12-mer was needed to reach more than 90% killing of C. albicans, whereas MUC7 12-mer achieved 95% killing within 45 min at this concentration. Both MUC7 12-mer and Hsn5 12-mer killed C. neoformans much faster than C. albicans. At concentrations of 30 µM, both peptides needed only 5 min to achieve complete killing for C. neoformans, whereas for C. albicans this was only accomplished after 45 min. However, at equally potent concentrations of the two peptides, MUC7 12-mer and Hsn5 12-mer showed similar rates of killing for both fungi (Figure 2 ).
Growth inhibitory activities of the combination of compounds using chequerboard assay
A two-dimensional chequerboard assay was used first to characterize interactions between MUC7 12-mer and other agents. In this method, one is looking for a reduction in the MIC of each compound in the presence of the other. The results are expressed in fractional inhibitory concentration index (FICI). Compared to the MICs obtained when each compound was used alone, MICs were substantially reduced, although to a variable extent, when the compounds were used in combinations. As shown in Table 3 
Growth inhibitory activities of MUC7 12-mer in combination with other antifungal agents using fungicidal assay
Recently, there have been some concerns that the FIC values determined by chequerboard assay are inherently prone to inaccuracies due to the possibility of partial inhibitory effects of the antimicrobial agents used individually. Thus, it is important to strengthen the data by combination killing assay. The effects of the MUC7 12-mer Figure 3 . However, in this assay, the concentration of only one agent can be varied (by serial dilution), while the concentration of the other is fixed (in contrast to the chequerboard assay, where there are serial dilutions of both agents). Compared to MUC7 12-mer alone, an enhanced effect on the loss of C. albicans viability was observed when MUC7 12-mer (at 12.5, and 6.25 µM) was combined with Hsn5 12-mer at 7.5 µM, or miconazole at 15 µM. The addition of amphotericin B at 7.5 µM had only a slightly increased effect on the activity of MUC7 12-mer at 12.5 µM concentration. A significant enhancement (P < 0.05) of activity of MUC7 12-mer was also found in killing of C. neoformans when MUC7 12-mer at 0.78 µM was combined with 0.78 µM of Hsn5 12-mer or 7.5 µM of miconazole. MUC7 12-mer induced a significant increase (P < 0.05) in the activity of the second agent (Hsn5 12-mer, amphotericin B, or miconazole) against both C. albicans and C. neoformans, compared to those of each second agent alone. The enhancement of MUC7 12-mer appeared to be concentration-dependent. Overall, these results showed consistency with those obtained in chequerboard assay.
Haemolytic activity
Since human erythrocytes are readily available, and their lysis is easy to monitor by measuring the release of haemoglobin, the haemolytic activity of antifungal agents is usually used as an indication for measuring their cytotoxicity. Effects of MUC7 12-mer, Hsn5 12-mer, magainin II, amphotericin B and miconazole on human red blood cells are shown in Figure 4 . Haemolysis assays were carried out under the following conditions: PBS, where the peptide antifungal activity is decreased and haemolysis masked due to high salt concentration, in IGP buffer (isotonic glucose phosphate buffer containing 287 mM glucose) and LYMG medium (modified, low salt RPMI 1640 medium, supplemented with 287 mM glucose). In IGP and LYMG, the peptide activity is retained and sugar provides osmotic stabilization in place of salt. Generally, the haemolysis of each test agent except amphotericin B was higher in IGP and LYMG than those in PBS (the test agents except amphotericin B did not exhibit remarkable haemolysis in PBS). At the highest concentration tested in this study (100 µM), conventional antifungal therapeutic agent amphotericin B exerted 100% haemolysis in all test media; and miconazole 98% and 44% in IGP and LYMG, respectively. MUC7 12-mer caused 4.3%, 56% and 35% haemolysis in PBS, IGP and LYMG, respectively. Compared to MUC7 12-mer, Hsn5 12-mer exerted less haemolysis (1%, 41%, 16%, respectively), whereas magainin, a membrane-active antimicrobial peptide, caused more haemolysis than MUC7 12-mer (92% in IGP and 65% in LYMG). This indicates that the two salivary peptides tested in this study show low cytotoxic activity.
Discussion
The search for novel antibacterial agents and the attempt to modify and improve the features of the currently available chemotherapeutic agents are in high demand as a consequence of the rapid spread of multidrug-resistant fungal pathogens. In this regard, naturally occurring antimicrobial peptides are an attractive option. In order to lower the cost of antimicrobial peptides, it is of significance to minimize fragment length to the length that preserves or even exceeds the antimicrobial activity of the parent molecule. 34, 35 The compact size of MUC7 12-mer reduces the cost of chemical synthesis. The activity of MUC7 12-mer is comparable to Hsn5 12-mer and conventional antimycotics used in this study, in both MIC tests (Table 1) and killing assays (Table 2 ). MUC7 12-mer has a very favourable spectrum In vitro time-kill assays demonstrated that, similar to the assays carried out in phosphate buffer, in LYM medium both MUC7 12-mer and Hsn5 12-mer exhibit concentration-dependent fungicidal activity. This is also consistent with the activity of other antifungal peptides. 31, 36, 37 The killing rate of Hsn5 12-mer in this study agreed with that of full-length Hsn5 molecule (24-mer). 38 However, to date no comparison of the killing rate of the two peptides at equal potent concentrations has been reported. This study showed that at the same molar concentrations the killing rate of MUC7 12-mer appeared to be faster than that of Hsn5 12-mer. However, when compared at equally potent concentrations, the killing rate was almost the same.
In this study, we also found both MUC7 12-mer and Hsn5 12-mer to kill C. neoformans faster than C. albicans. This, in agreement with previous studies, suggests that C. neoformans is more susceptible than C. albicans to these peptides. Electrostatic interactions between the CAMP and anionic microbial surface has been proposed as one of the important processes in the mode of CAMP action. 39, 40 C. neoformans is an encapsulated yeast with a highly negatively charged surface due to its polysaccharide capsule and melanin; 41 this may favour the association with MUC7 12-mer or Hsn5 12-mer, of cationic peptides with the net positive charge of 6 and 5, respectively.
Combination regimens exhibiting synergy could provide additional options for treating fungal infections. As pointed out in the Introduction, a combination of antimicrobial peptides with conventional antimycotics has been investigated by other researchers. [23] [24] [25] [26] [27] 42 Antifungal activity of amphotericin B was enhanced by Hsn5 23 and pneumocandin (a cyclic hexapeptide) derivatives. 24 A promoted antifungal activity was found in the combination of a membraneactive peptide (MP 11-mer) with fluconazole, 25 and the combination of lactoferrin peptide (LF 9-mer) with miconazole. 26 In agreement with these reports, MUC7 12-mer also showed enhancement of antifungal activity when combined with amphotericin B, or miconazole. Significantly, the combination of MUC7 12-mer with miconazole showed a synergic effect (FICI 0.25) against C. neoformans (Table  3) , and promoted antifungal activity (FICI 0.56) against C. albicans (however, no synergic effect was found). Moreover, in this study, we showed for the first time that the combination of two salivary antimicrobial peptides, MUC7 12-mer and Hsn5 12-mer, exhibits synergic activity against C. neoformans. These findings may have substantial significance for combination therapy. Beneficial effects of combination therapy may be slowing down the development of drug-resistant subpopulations of pathogenic organism 32 and a reduction in the adverse effects.
Generally, the synergic effects of two agents can result from the combination of two different mechanisms of action. We found synergy between miconazole and MUC7 12-mer. Miconazole is one of the azole-based antifungal therapeutic agents. Azole antifungals inhibit the formation of ergosterol (the major component of fungal cell membrane) via inhibition of enzyme(s) involved in ergosterol biosynthesis. The peptides exert their effect through different mechanisms of action. Our recent study demonstrated that even two salivary molecule-derived peptides, MUC7 20-mer and full-length 
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Hsn5 appear to work by distinct mechanisms. MUC7 20-mer fungicidal activity, unlike that of Hsn5, 43 does not require an active cell metabolic state. 18 MUC7 20-mer was able to cross the fungal cell membrane and to accumulate inside the cells but unlike Hsn5 and C. albicans, 43 mitochondria are not the targets of MUC7 20-mer for both C. albicans and C. neoformans. 18 The internalization of MUC7 20-mer, unlike Hsn5, was not inhibited by low temperature, sodium azide or carbonyl cyanide m-chlorophenylhydrazone (CCCP), an uncoupler of cellular respiration. 18 Based on the above studies on the mechanism of action of the full-length Hsn-5 and MUC7 20-mer, 18,20,44 we speculate that the synergic effect between MUC7 12-mer and Hsn5 12-mer may be the result of two different mechanisms of action by these two peptides.
Haemolytic effect is believed to be one of the adverse effects of some cationic antimicrobial peptides such as magainin, protegrin, mellitin, defensin and cecropin. 45 Most cationic antimicrobial peptides (CAMPs) do not show haemolysis in PBS (physiological conditions) partly because of the protection by high ionic strength. 19 Some CAMPs, however, still show haemolysis when examined under physiological conditions. 46 Compared with amphotericin B, MUC7 12-mer and Hsn5 12-mer showed almost no haemolytic activity against human erythrocytes in PBS (at peptide concentrations up to 100 µM; Figure 4 ). In the assays conducted in low ionic strength isotonic glucose phosphate buffer (IGP) or a low ionic strength broth (LYM, supplemented with glucose), the haemolysis caused by the peptides increased. However, MUC7 12-mer and Hsn5 12-mer still showed lower haemolysis than magainin and the two classical antifungal therapeutic agents. These results indicate that these peptides are not toxic to mammalian cells under physiological conditions.
In summary, this study shows that MUC7 12-mer and Hsn5 12-mer have many potential advantages as candidates for antifungal agents. First, MUC7 12-mer and Hsn5 12-mer show fungicidal activity against pathogenic and resistant fungi and a fast killing rate but low cytotoxicity for mammalian cells (based on haemolytic assays carried out both in PBS, and low ionic strength buffer and medium). Second, the combination of MUC7 12-mer with miconazole shows a synergic effect (FICI 0.25) against C. neoformans and an enhanced antifungal activity (FICI 0.56) against C. albicans. Finally, combination of MUC7 12-mer and Hsn5 12-mer exhibits synergic activity against C. neoformans. On the basis of these results, we suggest that these peptides can be attractive and novel candidates for development into effective and safe antimicrobial therapeutic agents for topical and possibly systemic applications. Human red blood cells (final concentration 0.5%) were incubated for 1 h at 37°C with a two-fold dilution series of peptides. Haemolysis was determined by an absorbance reading of the supernatant at 450 nm and compared to haemolysis achieved with 1% Triton X-100 (reference for 100% haemolysis). Values represent the mean of three independent experiments, each of which was done in duplicate. PBS, phosphate buffered saline; IGP, 1 mM potassium phosphate buffer, pH 7.0, supplemented with 287 mM glucose as an osmoprotectant; LYMG, LYM medium supplemented with 287 mM glucose as an osmoprotectant.
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